Press and Publications
Press Releases
June 15, 2017: Protein Potential, LLC Publishes on its Anthrax and Shigellosis Vaccines Based on Oral Typhoid Fever Vaccine Platform
September 25, 2012: Protein Potential, LLC Awarded $1.8 Million to Develop Multi-Component New Malaria Vaccine Solution
September 19, 2012: Protein Potential, LLC and Aduro Biotech Inc. awarded Phase 1 SBIR to develop two novel malaria vaccines
April 20, 2010: Protein Potential, LLC Awarded $3 Million U.S. NIH Phase II Small Business Innovation Research Grant
August 29, 2009: Potential New Treatment for Avian Influenza
Publications
BKL Sim et al., Protection against inhalation anthrax by immunization with Salmonella enterica serovar Typhi Ty21a stably producing protective antigen of Bacillus anthracis, NPJ Vaccines, 2017
Y Wu et al., Development of a Live Attenuated Bivalent Oral Vaccine Against Shigella sonnei Shigellosis and Typhoid Fever, JID, 2017
Editorials
Avian Influenza: Exploring All the Avenues
Meta-Analysis: Convalescent Blood Products for Spanish Influenza Pneumonia: A Future H5N1 Treatment?
Grants, Awards, and Collaborations
Live Attenuated Oral Typhoid-Shigellosis Vaccine
2015-2017 - Principal Investigator - NIH/Small Business Innovation Research Grant (1R43AI106158-01)
Multi-Ligand Merozoite Invasion Blocking Malaria Vaccine
2012-2014 - Principal Investigator - NIH/Small Business Innovation Research Grant (1R43AI096632-01A1)
Development of Enabling Vector/Antigen Expression Technology for an Orally Delivered Multivalent Vaccine for Simultaneous Anthrax-Plague Prophylaxis
2012-2017 - Principal Investigator - R01 Partnerships for Biodefense (1 R01 AI098884)
Plasmodium vivax Recombinant CS Protein Vaccine for Malaria
2010-2013 - Principal Investigator - NIH/Small Business Innovation Research Grant (2-R44-AI058373-03A2)
Multi-stage Multi-antigen Vaccine for Interrupting Malaria Transmission
2012-2014 - Principal Investigator - NIH/Small Business Innovation Research Grant (1R43AI100531-01)
Live Attenuated Oral Anthrax Vaccine
2010-2012 - Principal Investigator - NIH/Small Business Innovation Research Grant (1R43AI091273-01)
Immunizing Against Malaria by Inducing Both Protective Antibodies and CD8 T Cells
2012-2014 - Principal Investigator - NIH/Small Business Innovation Research Grant (1R43AI098151-01)
Recombinant Plasmodium falciparum CelTOS Vaccine
2008-2010 - Principal Investigator - NIH/Small Business Innovation Research Grant (1-R43-AI077260-01A1)
Production of purified recombinant proteins for development of vaccines of military importance
2005-2007 - Principal Investigator - OSD/Small Business Innovation Research Grant Phase II (Ser 341/037)
A SARS-CoV Spike Protein Vaccine
2004-2006 - Principal Investigator - NIH/Small Business Innovation Research Grant (1-R43-AI060098-01)
Plasmodium vivax Recombinant CS Protein Vaccine
2005-2007 - Principal Investigator - NIH/Small Business Innovation Research Grant –(1-R43-AI058373-01)
Attenuated Sporozoite Malaria Vaccine
2007-2009 - Principal Investigator - Program for Appropriate Technology in Health (PATH) and Sanaria Inc.
A Tetravalent Dengue Recombinant Protein Vaccine
2004-2006 - Principal Investigator - NIH/Small Business Innovation Research Grant (1-R43-AI058622-01)